Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
A novel assay was shown to precisely quantify CAR T cells in circulation and distinguish responders from nonresponders.
Responses lasted for a median of 21.8 months, and patients had a median PFS of 18.8 months.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Investigators performed post hoc subgroup analyses by age in patients with relapsed/refractory indolent lymphoma from the MAGNIFY study.
Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.
Patients with AML or MDS were significantly more likely to die from COVID-19 vs other HMs. Most treatments did not improve survival outcomes — except corticosteroids.
The limited data underscore “a potential role for passive immunity in this disease,” according to the presenting researcher.
Want to read more?
Please login or register first to view this content.